User login
NEWPORT BEACH, CALIF. – There is a role for topical cidofovir in the treatment of recalcitrant warts in children, Dr. James R. Treat said at Skin Disease Education Foundation’s Women’s & Pediatric Dermatology Seminar.
The drug is not to be used as a first, second, or even third-line option, but can be effective in stubborn cases, said Dr. Treat of Children’s Hospital of Philadelphia.
In an interview at the meeting, Dr. Treat explained how and when he incorporates topical cidofovir and other strategies into managing verruca vulgaris when other treatments fail.
Dr. Treat had no relevant financial conflicts to disclose.
SDEF and this news organization are owned by Frontline Medical Communications.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
NEWPORT BEACH, CALIF. – There is a role for topical cidofovir in the treatment of recalcitrant warts in children, Dr. James R. Treat said at Skin Disease Education Foundation’s Women’s & Pediatric Dermatology Seminar.
The drug is not to be used as a first, second, or even third-line option, but can be effective in stubborn cases, said Dr. Treat of Children’s Hospital of Philadelphia.
In an interview at the meeting, Dr. Treat explained how and when he incorporates topical cidofovir and other strategies into managing verruca vulgaris when other treatments fail.
Dr. Treat had no relevant financial conflicts to disclose.
SDEF and this news organization are owned by Frontline Medical Communications.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
NEWPORT BEACH, CALIF. – There is a role for topical cidofovir in the treatment of recalcitrant warts in children, Dr. James R. Treat said at Skin Disease Education Foundation’s Women’s & Pediatric Dermatology Seminar.
The drug is not to be used as a first, second, or even third-line option, but can be effective in stubborn cases, said Dr. Treat of Children’s Hospital of Philadelphia.
In an interview at the meeting, Dr. Treat explained how and when he incorporates topical cidofovir and other strategies into managing verruca vulgaris when other treatments fail.
Dr. Treat had no relevant financial conflicts to disclose.
SDEF and this news organization are owned by Frontline Medical Communications.
The video associated with this article is no longer available on this site. Please view all of our videos on the MDedge YouTube channel
AT SDEF WOMEN’S & PEDIATRIC DERMATOLOGY SEMINAR
